NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

ATL, How could the control group most of whose members received DCVax-L after progression, only display an mOS of about 14-16 months? This only seems logical if the late administration of DCVax-L was of little benefit or if the initial exclusion of most of the pseudo-progressors from this trial constituted a substantial longevity reducing factor.

I am wondering whether the thorough exclusion of radiotherapy induced pseudo-progressors from this trial had shortened the mOS of both the Control and Treatment groups.

It seems logical to me that had the pseudo-progressors not been removed from the trial, the mOS of both Control and Treatment groups would have been even longer and the results when compared to other contemporaneous trials would have displayed an even greater superiority. I trust that if that is true, the publication will deal with it effectively.